文献速递外周动脉疾病

胫动脉孤立性球囊血管成形术后双通路抑制与双联抗血小板治疗的比较

Dual pathway inhibition versus dual antiplatelet therapy following isolated tibial balloon angioplasty for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2026-09-08

本研究为回顾性队列研究,纳入2022年1月至2024年7月因慢性肢体威胁性缺血(CLTI)接受孤立性胫动脉球囊血管成形术的199例患者,比较双通路抑制(DPI,利伐沙班2.5mg每日两次+阿司匹林)与双联抗血小板治疗(DAPT)的结局。12个月时DPI组大截肢和靶病变血运重建(TLR)均低于DAPT组,大出血未增加,全因死亡无差异。

要点

  • 两组均无大出血事件,轻微出血率低且相当。

核心结论

  • 孤立性胫动脉球囊血管成形术后,低剂量利伐沙班联合阿司匹林的双通路抑制与双联抗血小板治疗相比,可降低大截肢和靶病变血运重建,且不增加大出血。

研究设计与样本

  • 回顾性队列研究,纳入2022年1月至2024年7月因CLTI接受孤立性胫动脉球囊血管成形术的患者199例,其中DAPT组102例,DPI组97例。

主要发现

  • 两组均无大出血事件,轻微出血率低且相当。

临床怎么用

  • 对于因CLTI接受孤立性胫动脉球囊血管成形术的患者,可考虑使用低剂量利伐沙班联合阿司匹林的双通路抑制以降低大截肢和TLR风险。

局限性

  • 本研究为回顾性队列分析,样本量有限,需更大规模前瞻性研究证实并明确最佳抗血栓策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal antithrombotic therapy following infrapopliteal angioplasty for chronic limb-threatening ischemia (CLTI) remains uncertain. Dual pathway inhibition (DPI) with low-dose rivaroxaban plus aspirin has demonstrated benefit in broader peripheral arterial disease populations, including after lower-extremity revascularization; however, evidence specific to isolated crural interventions is limited. Currently, patients receive either DPI or dual antiplatelet therapy (DAPT) based on surgeons' choice, and this study will compare the outcomes of the two regimens in a retrospective cohort analysis based on the hypothesis that DPI provides superior prevention of thromboembolic events after angioplasty. METHODS: A retrospective cohort study was conducted including patients undergoing isolated tibial balloon angioplasty for CLTI between January 2022 and July 2024. Patients receiving DAPT (aspirin plus clopidogrel) were compared with those receiving DPI (rivaroxaban 2.5 mg twice daily plus aspirin) lifelong. Patients undergoing multilevel interventions, stenting, drug-coated balloon angioplasty, thrombolysis, or treatment for claudication were excluded. Primary outcomes included major limb amputation and all-cause mortality. Secondary outcomes included target lesion revascularization (TLR), acute limb ischemia, and bleeding complications. RESULTS: A total of 199 patients met the inclusion criteria, including 102 treated with DAPT and 97 treated with DPI. Baseline demographic and clinical characteristics were broadly comparable between groups. At 12 months, major limb amputation occurred in 27 patients (26.5%) receiving DAPT and 17 patients (17.5%) receiving DPI (P = .04), corresponding to an absolute risk reduction of 9.0% and a number needed to treat of 11. TLR was required in 14 patients (13.7%) in the DAPT group and five patients (5.2%) in the DPI group (P = .04), corresponding to an absolute risk reduction of 8.5% and a number needed to treat of 12. Acute limb ischemia occurred in four patients (3.9%) receiving DAPT and one patient (1.0%) receiving DPI (P = .40). One-year mortality was similar between groups (3.9% vs 3.1%; P = .79). No major bleeding events occurred in either group, whereas minor bleeding rates were low and comparable. CONCLUSIONS: Among patients undergoing isolated tibial angioplasty for CLTI, DPI with low-dose rivaroxaban plus aspirin was associated with reduced major limb amputation and TLR compared with DAPT, without an increase in major bleeding. Larger prospective studies are warranted to confirm these findings and define the optimal antithrombotic strategy following infrapopliteal intervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Abdelmalak M, Abdelaziz I, Abdulaal U, et al. Dual pathway inhibition versus dual antiplatelet therapy following isolated tibial balloon angioplasty for chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 42710605. doi:10.1016/j.jvs.2026.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。